

Special Issue

Research on MHC Background and TCR Diversity in Vaccinology

Message from the Guest Editor

Tailored vaccine candidate T cell antigens are playing a crucial role in designing and developing promising immunization strategies against e.g., viral infections. In contrast to traditional vaccines based on attenuated or inactivated pathogens that are often sufficiently immunogenic without added adjuvants, safer protein-based vaccines require adjuvants to induce a protective and long-lasting immune response. Antigen (Ag)-specific CD4 T helper cells play an essential role in the generation and maintenance of long-lasting humoral and cellular immunity and are therefore important vaccine targets. In this context, we would like to encourage and appreciate the submission of recent advancements in providing evidence for the dependence on the MHC background and TCR diversity for the vaccination success to this special issue. Contributions addressing aspects relevant for designing vaccines against zoonotic or emerging diseases, such as SARS-CoV-2, will also be considered for publication.

Guest Editor

Dr. Sabine E. Hammer

Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria

Deadline for manuscript submissions

closed (31 May 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/73909

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).